0001213900-24-030961.txt : 20240405 0001213900-24-030961.hdr.sgml : 20240405 20240405214526 ACCESSION NUMBER: 0001213900-24-030961 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schneiderman Daniel H CENTRAL INDEX KEY: 0001565536 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40804 FILM NUMBER: 24827969 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVE. SUITE 304 STREET 2: SUITE 207 CITY: BROOKLYN STATE: NY ZIP: 11226 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pasithea Therapeutics Corp. CENTRAL INDEX KEY: 0001841330 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851591963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 BUSINESS PHONE: 8184226172 MAIL ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 4/A 1 ownership.xml X0508 4/A 2024-03-01 2024-03-01 0 0001841330 Pasithea Therapeutics Corp. KTTA 0001565536 Schneiderman Daniel H 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 0 1 0 0 Chief Financial Officer 0 Stock Option (right to buy) 8.13 2024-03-01 4 A 0 10000 0 A 2034-02-28 Common Stock 10000 10000 D Stock Option (right to buy) 8.13 2024-03-01 4 A 0 5927 0 A 2034-02-28 Common Stock 5927 5927 D The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date. The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024. On January 2, 2024, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Common Stock, and the exercise price and shares of Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. /s/ Daniel Schneiderman 2024-04-05